THE HY-BRID PATENT IN HYALURONIC ACID FILLERS

The Hy-BRID patent represents a groundbreaking advancement in the production of hyaluronic acid-based fillers, offering an innovative solution to enhance product plasticity while ensuring lasting and stable effects. Traditional fillers often struggle with issues like volume inconsistency and imprecision due to the use of irregularly sized particles, limiting their effectiveness. Hy-BRID overcomes these challenges, setting new benchmarks in the field of aesthetic rejuvenation
and enhancement. 

A core strength of Hy-BRID technology lies in its ability to achieve an optimal density of hyaluronic acid and uniformly sized molecules. This
results in fillers with exceptional viscoelasticity and uniform absorption, ensuring long-lasting results without the frequent need for maintenance treatments. The precise calibration of hyaluronic acid particles to uniform size is vital to achieving a natural-looking effect, allowing seamless adaptation to different facial areas, from fine lines to deeper volume loss. This guarantees a harmonious, personalized result that complements each patient’s unique features. The cosmetic industry has widely sought after this property of HA with several cosmetic products like HA supplements, serums, moisturizers, and dermal fillers. Because of its high water restricting properties, HA makes for the perfect dermal filler. One caveat of HA is that its natural form, when infused into the skin, is quickly lost. However, ReMedium’s patented MCL technology makes up for this, giving forth a stable and long-lasting HA dermal filler.